ZA966953B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number
ZA966953B
ZA966953B ZA9606953A ZA966953A ZA966953B ZA 966953 B ZA966953 B ZA 966953B ZA 9606953 A ZA9606953 A ZA 9606953A ZA 966953 A ZA966953 A ZA 966953A ZA 966953 B ZA966953 B ZA 966953B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
stimulators
ifn
healing
gamma
Prior art date
Application number
ZA9606953A
Other languages
English (en)
Inventor
Mark William James Ferguson
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of ZA966953B publication Critical patent/ZA966953B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
ZA9606953A 1995-08-18 1996-08-16 Pharmaceutical composition. ZA966953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
ZA966953B true ZA966953B (en) 1998-02-16

Family

ID=10779448

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606953A ZA966953B (en) 1995-08-18 1996-08-16 Pharmaceutical composition.

Country Status (13)

Country Link
EP (2) EP0972521B1 (ja)
JP (2) JP4070809B2 (ja)
AT (2) ATE231728T1 (ja)
AU (1) AU713809B2 (ja)
CA (1) CA2229590C (ja)
DE (2) DE69626050T2 (ja)
DK (2) DK0845007T3 (ja)
ES (2) ES2164911T3 (ja)
GB (1) GB2304342A (ja)
HK (1) HK1023516A1 (ja)
PT (2) PT972521E (ja)
WO (1) WO1997007136A2 (ja)
ZA (1) ZA966953B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3579355B2 (ja) 1998-12-09 2004-10-20 プロテイン デザイン ラブス インコーポレイティド ヒトの乾癬を予防及び治療するための乾癬モデル動物
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
JP2003500113A (ja) * 1999-05-26 2003-01-07 ザ ブリガム アンド ウイミンズ ホスピタル、 インコーポレイテッド アルファ平滑筋アクチン活性を調節する薬剤の治療的使用
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
EP0311616B1 (en) * 1986-06-17 1991-09-25 Biogen, Inc. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents for treating diseases
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ES2096553T3 (es) * 1988-12-19 1997-03-16 American Cyanamid Co Metodo para el tratamiento de choque endotoxico en un animal mamifero.
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
EP0393502B1 (en) * 1989-04-19 1995-12-27 F. Hoffmann-La Roche Ag Soluble interferon-gamma receptors and methods for their production
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
WO1992006115A1 (en) * 1990-09-27 1992-04-16 Schering Corporation Antagonists of human gamma interferon
EP0526630A4 (en) * 1991-02-22 1993-08-11 Amgen Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
CA2149785A1 (en) * 1992-11-20 1994-06-09 Gail F. Seelig Antagonists of human gamma interferon
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
JPH09506263A (ja) * 1993-12-09 1997-06-24 アゲット，ミヒェル ＩＦＮ−γレセプターβ−鎖およびその誘導体

Also Published As

Publication number Publication date
DE69626050T2 (de) 2004-01-22
AU713809B2 (en) 1999-12-09
EP0972521A1 (en) 2000-01-19
DE69626050D1 (de) 2003-03-06
EP0972521B1 (en) 2003-01-29
AU6707196A (en) 1997-03-12
JP4070809B2 (ja) 2008-04-02
JP2007119497A (ja) 2007-05-17
HK1023516A1 (en) 2000-09-15
EP0845007A2 (en) 1998-06-03
JPH11511160A (ja) 1999-09-28
WO1997007136A3 (en) 1997-08-21
EP0845007B1 (en) 2001-11-07
GB2304342A (en) 1997-03-19
WO1997007136A2 (en) 1997-02-27
PT845007E (pt) 2002-03-28
ATE208402T1 (de) 2001-11-15
ATE231728T1 (de) 2003-02-15
JP4616291B2 (ja) 2011-01-19
CA2229590A1 (en) 1997-02-27
GB9516967D0 (en) 1995-10-18
DK0972521T3 (da) 2003-05-05
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
PT972521E (pt) 2003-06-30
DK0845007T3 (da) 2001-12-17
CA2229590C (en) 2010-10-12
ES2192018T3 (es) 2003-09-16
ES2164911T3 (es) 2002-03-01

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
ZA966578B (en) Pharmaceutical composition.
ZA966953B (en) Pharmaceutical composition.
AU623805B2 (en) New use of anti-progestomimetic compounds
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU1506692A (en) Pharmaceutical compositions
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
SI1083887T1 (sl) Farmacevtski sestavki za zdravljenje ulkusov
IL119403A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
IL119250A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
IL115200A0 (en) Pharmaceutical compositions for the treatment of cancer
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
IL119219A0 (en) Pharmaceutical compositions for treatment of the eyes
IL122883A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL127102A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IL137190A0 (en) Pharmaceutical compositions for the treatment of dyskinesias
IT1269740B (it) Derivati di combretastatine ad attivita' anti-tumorale e procedimento per la loro preparazione